[verwijderd] 15 december 2006 20:58 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:aossa schreef:Rabies monoclonal antibodies 50 milj. doden per jaar Zoveel doden nu ook weer niet: Uit het bericht: 40.000 tot 70.000 doden per jaar Aanbevelingen 0 ” Quote Reageren Niet oké
aossa 16 december 2006 14:11 auteur info aossa Lid sinds: 23 mei 2003 Laatste bezoek: 12 mrt 2025 Aanbevelingen Ontvangen: 4053 Gegeven: 3339 Aantal posts: 17.622 quote:dedokter schreef:[quote=aossa]Rabies monoclonal antibodies 50 milj. doden per jaar [/quote]Zoveel doden nu ook weer niet: Uit het bericht: 40.000 tot 70.000 doden per jaar Klopt, die $$$-tekens in beide ogen deden het ;-) Aanbevelingen 0 ” Quote Reageren Niet oké
gogogoo 18 december 2006 22:29 auteur info gogogoo Lid sinds: 28 feb 2006 Laatste bezoek: 10 aug 2023 Aanbevelingen Ontvangen: 1600 Gegeven: 808 Aantal posts: 6.042 Bharat Biotech launches anti-rabies vaccineTuesday December 19 2006 00:00 ISTIANSHYDERABAD: Bharat Biotech International Ltd (BBIL) on Monday launched a new anti-rabies vaccine Rabirix that can be used both for prevention as also for treatment in case of infection due to animal bite or contact with saliva of an infected animal.Rabirix has been indigenously developed by BBIL and "can be used for both prophylactic (vaccine-pre bite) and therapeutic (post bite) treatments", said Krishna M Ella, chairman and managing director at the launch. Julie Gerberding, director of the US-based Centres for Disease Control and Prevention (CDC), was also present.Rabirix is a purified vero cell based rabies vaccine (PVRV), which has been extensively evaluated clinically for pre-bite and post-bite applications, and has proven to be well tolerated with minimal or no side effects.The immune sera samples from phase III clinical trials have been analysed at the Pune-based National Institute of Virology and the efficacy of the product has been established.Rabies is an acute viral encephalitis transmitted from an infected animal to human by exposure to saliva.Human infection with rabies is nearly always secondary to animal bite, with dog being the major reservoir for human Rabies. Once clinical symptoms have occurred, the disease is almost invariably fatal.No tests are currently available to diagnose rabies infection in humans before the onset of clinical disease.Four million people are exposed to the rabies virus worldwide every year and 60,000 people fall victim to it. In India, three million people undergo anti-rabies treatment and 30,000 deaths are reported annually which accounts for 50 percent of mortality from rabies worldwide."The rabies vaccines contribute approximately 50 percent of the vaccine market in India in terms of value. Currently, the market size of rabies vaccines is estimated to be around Rs 2.5 billion," said Ella.BBIL has created a dedicated marketing division christened IMMUTIKA (Immunisation and Tika) to promote vaccines.www.newindpress.com/NewsItems.asp?ID=...-=-=-Ik ben benieuwd hoeveel het vaccin kost. Aanbevelingen 0 ” Quote Reageren Niet oké
pim f 10 januari 2007 22:00 auteur info pim f Lid sinds: 29 sep 2004 Laatste bezoek: 07 mrt 2025 Aanbevelingen Ontvangen: 874 Gegeven: 783 Aantal posts: 4.109 Rabies and snake bite care boostBy Immogen FoulkesBBC NewsRabies treatment supplies are limited in poorer countries. A global US$10million plan to improve treatment of rabies, snake bites and scorpion stings is being drawn up by the World Health Organization (WHO). Experts are meeting in Geneva on Wednesday to consider the issue.The WHO says thousands of people - mainly the young - die unnecessarily each year because they do not have access to the treatment they need. The new plan should make available millions more doses of anti-rabies serum and anti-snake bite venom.The WHO estimates that more than 12 million people are attacked each year by dogs, snakes or scorpions. Around 8 million ought to have precautionary treatment for rabies following a dog bite but only 6% get it. Rabies remains the 10th most common cause of death from infections in humans.It is a disease which is 100% fatal if untreated - but also 100% preventable if treated early enough with the right drugs.Production lowHowever, production of the serum to treat rabies and of anti-venom treatment against snake bites is low because demand has fallen in wealthier countries and profits have dropped. That means the treatments have become either unavailable or unaffordable in the countries - mainly in Africa and Asia - which still desperately need them. Snake bite victims in particular, the WHO says, are forced to rely on traditional remedies. Many die or are left with serious neurological disorders.Under the new plan, the WHO plans to improve treatment availability by transferring serum production technology to developing countries. It also plans a new global standard of quality control and training for local manufacturers.Howard Zucker, WHO Assistant Director-General for Health Technologies and Pharmaceuticals, said: "We need to boost local manufacturers' capacity and improve the delivery of products to remote rural areas. "There are effective solutions that could save millions of lives." news.bbc.co.uk/2/hi/health/6247761.stm Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 22 juni 2007 19:59 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Weinig nieuws........A phase Ib study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteers ISRCTN ISRCTN12693237 Title of trial/grant title A phase Ib study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteers Acronym N/A Serial number at source RAB-M-A002 Study hypothesis First time in Asian subjects study of CL184, a human monoclonal antibody cocktail against rabies virus. Ethics approval Received from 'Ethics R'US', based in Mumbai (India). Study design Randomised, double-blind, placebo controlled, phase Ib study Countries of recruitment India Disease/condition/study domain Post-exposure prophylaxis for World Health Organisation (WHO) category III rabies exposures Participants - inclusion criteria 1. Healthy volunteers between 19 and 55 years of age 2. No previous treatment with rabies vaccine 3. Body Mass Index (BMI) between 18 and 28 kg/m^2 Participants - exclusion criteria 1. Pregnant women, women planning to become pregnant and breastfeeding women 2. A history of or currently active clinically significant cardiac (including clinically significant abnormalities on Electrocardiogram [ECG] according to Principal Investigator [PI]), pulmonary, gastrointestinal, hepatic, renal, pancreatic, or neurological disease Anticipated start date 02/04/2007 Anticipated end date 08/07/2007 Status of trial Ongoing Target number of participants 44 Interventions Part 1: The study subjects will receive one dose of CL184 intramuscularly at day 0 and will be followed up over 42 days. Part 2: The study subjects will receive one dose of CL184 on day 0 in combination with rabies vaccine on days 0, 3, 7, 14 and 28. Primary outcome measure(s) Safety and tolerability: this is assessed throughout the study, i.e., over 42 days. Secondary outcome measure(s) 1. Neutralising activity: this analysis is made at Day 14 and at all other timepoints up to day 42 2. Pharmacokinetics of CL184: this is a time-dependent parameter and analysis is performed over the full study duration, i.e., 42 days Sources of funding Crucell Holland BV (The Netherlands) Contact name Dr Pramod Kabra Address Dhirubhai Ambani Life Sciences Centre (DALC) Plot R-282, TTC Area of MIDC Rabale, Navi City/town Mumbai Zip/Postcode 400 701 Country India Sponsor Crucell Holland BV (The Netherlands) Address Archimedesweg 5 City/town Leiden Zip/Postcode 2333 CN Country Netherlands Sponsor website: www.crucell.com Date applied 10/05/2007 Last edited 22/06/2007 Date ISRCTN assigned 22/06/2007 www.controlled-trials.com/ISRCTN12693237 Aanbevelingen 1 ” Quote Reageren Niet oké
[verwijderd] 3 oktober 2007 10:01 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Even draadje naar boven halen:A phase I study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteersAnticipated start date 06/12/2006 Anticipated end date 18/05/2007 Status of trial Completed www.controlled-trials.com/mrct/trial/...A phase Ib study to assess safety and tolerability and neutralising activity of CL184 in healthy volunteersAnticipated start date 02/04/2007 Anticipated end date 08/07/2007 Status of trial Completed www.controlled-trials.com/mrct/trial/... Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.